Angiogenesis or new vessel formation is an essential component in the growth and progression of neoplasms and there is growing evidence of its importance in hematological malignancies including multiple myeloma (MM). Vascular endothelial growth factor (VEGF) is believed to play a role in tumor angiogenesis. We studied the expression of VEGF and its receptors (VEGFR1 or Flt-1 and VEGFR2 or Flk-1/KDR) by myeloma cell lines and plasma cells isolated from patients, using different methods. VEGF expression by the plasma cells was demonstrated by immunohistochemistry in 18 of 20 patients with MM. Enzyme-linked immunosorbent assay demonstrated VEGF secretion in all six different myeloma cell lines studied. Five patient marrow samples and seven different myeloma cell lines were then studied for VEGF mRNA expression by reverse-transcriptase polymerase chain reaction (RT-PCR), which was positive in all. We further evaluated the expression of both VEGFR1 and VEGFR2 in different myeloma cell lines and five sorted myeloma bone marrow samples by RT-PCR. All the myeloma cell lines expressed VEGFR1 and three of the cell lines expressed VEGFR2. VEGFR1 expression was detected in all and VEGFR2 in all but one of the sorted marrow samples. Increased expression of VEGF by the myeloma cells taken in the context of the suspected prognostic value of marrow angiogenesis suggests a pathogenetic role for this cytokine and presence of its receptors on myeloma cells points toward an autocrine mechanism. Demonstration of the presence of VEGFR2 in our study provides a potential biological explanation for the preclinical activity observed with VEGFR2 inhibitors.
Introduction
Multiple myeloma (MM) is characterized by a clonal proliferation of abnormal plasma cells in the bone marrow resulting in a variety of different clinical manifestations like osteolytic bone lesions leading to pathologic fractures, anemia, life-threatening hypercalcemia and renal failure. It accounts for more than 10% of all hematological malignancies and nearly 1% of all malignancies. It is estimated that there will be 14 600 new patients with a diagnosis of myeloma in the United States alone during the year 2002 and there will be 10 800 estimated deaths due to myeloma in the same period. 1 The median survival from diagnosis among patients treated with conventional chemotherapy is 3-4 years. 2 Introduction of high-dose chemotherapy with stem cell rescue has led to improved survival, but these patients eventually relapse from their disease and it remains an incurable disease with the currently available therapeutic modalities. 3 Angiogenesis or new blood vessel formation from existing blood vessels (in contrast to vasculogenesis or de novo formation of blood vessels) occurs physiologically during normal growth, tissue healing and regeneration. The role of abnormal, increased angiogenesis in the development and spread of tumors had been suspected for nearly two decades and is being increasingly recognized. 4 Increasing levels of tumor angiogenesis has been associated with poor prognosis for a variety of hematological malignancies as well as solid tumors. As in solid tumors, new vessel formation (occurring in the bone marrow) seems to play an important role in the pathophysiology of myeloma, 5-8 leukemias 9,10 and in myelofibrosis. 11 Increased bone marrow microvessel density in patients with myeloma appears to be a powerful prognostic indicator. 7 Various cytokines have been invoked as being responsible for driving the process of neovascularization seen in the setting of solid tumors and hematological malignancies. 12 Vascular endothelial growth factor (VEGF) appears to have a particularly important role in the biology of MM. 13, 14 Studies have shown that myeloma cells are capable of secreting VEGF contributing to new vessel formation in the bone marrow in myeloma. In turn, the microvascular endothelial cells as well as the marrow stromal cells are stimulated by the VEGF resulting in increased secretion of interleukin (IL)-6, which has been shown to be a potent growth factor for the malignant plasma cells. 15, 16 An autocrine pathway of myeloma cell stimulation by VEGF may also exist in addition to this paracrine pathway. We examined the expression of VEGF and their receptors by different methods on the plasma cells to examine this hypothesis further.
Methods and materials

Isolation of patient plasma cells
Bone marrow samples were obtained from patients with MM and plasma cells were isolated from the patient samples using MACS separation columns using antibodies against CD138 as described by the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany). These cells were further analyzed by Wright-Giemsa stain and a purity of over 96% was confirmed.
Myeloma cell lines and cell culture
Eight different myeloma cell lines were used for the study (ARH9, OCI-My5, 17 ). All cell lines were maintained at 371C in RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin, streptomycin and L-glutamine. Three of these cell lines, KP6, ANBL-6 and KAS 6/1, were also supplemented with IL-6 at 5 ng/ml.
Enzyme-linked immunosorbent assay
Intracellular and secreted levels of VEGF were estimated by enzyme-linked immunosorbent assay (ELISA) using Quantikine s human VEGF assay (R and D systems, Minneapolis, MN, USA). For intracellular levels of VEGF, 5 Â 10 6 cells from each cell line were washed in RPMI Â 2, snap frozen in liquid nitrogen, and then thawed at 371C. The snap freezing and thawing was repeated two more times. Cellular debris was then spun down and supernatant saved for analysis. Secreted levels were estimated using cell culture supernatants taken on day 7 from each cell line. Briefly, 200 ml of cell culture supernatant, cell lysate or standard (recombinant human VEGF 165 ) was added to the microplate wells with the recommended diluent and incubated at room temperature for 2 h. The wells were washed and 200 ml of VEGF conjugate (polyclonal antibody against VEGF conjugated to horseradish peroxidase) was added and further incubation carried out at room temperature for 2 h. The wells were washed and 200 ml of hydrogen peroxide and tetramethylbenzidine was added and incubated for 20 min at RT. After stopping the reaction with 2 N sulfuric acid, the optical density was read at 450 nm using a microtiter plate reader.
Reverse-transcriptase polymerase chain reaction
Total RNA was isolated from cell lines and patient samples using an RNeasy s Kit as described by the manufacturer (Qiagen, Inc., Hilden, Germany). To generate cDNA and for amplification, 100 ng of RNA was used in a one-step reverse-transcriptase polymerase chain reaction (RT-PCR) kit as described by the manufacturer (Qiagen, Inc., Hilden, Germany). Nested PCR was performed to detect VEGFR1 and VEGFR2, and one round of PCR to detect VEGF. We chose an RT-nested-PCR approach to improve the sensitivity for detection of the VEGF receptors, since previous studies using RT single-step PCR have failed to demonstrate its presence consistently. Amplification of the housekeeping gene b-actin was used to verify mRNA isolation and RT-PCR techniques. Primer sequences were as follows: PCR-amplified products were electrophoresed in 1.0% agarose gel and stained with ethidium bromide. Expression was verified using ABI Prism 377 DNA Sequencer (Perkin-Elmer, Lincoln, NE, USA). Precautions were taken to avoid contamination and negative controls were run with each step. Preparation of samples and PCR reactions were carried out in different areas. Quantitative RT-PCR for VEGF transcripts was carried out with the RNA Amplification Kit-SYBR Green I (Molecular Probes, Eugene, OR, USA) according to the manufacturer's instructions using the LightCycler (Roche Diagnostics GmbH, Mannheim, Germany). Quantifications were made with a DNA external standard generated by PCR. The VEGF estimations were normalized using the housekeeping gene GAPDH. Primers were designed using Oligo 6.24 software (Molecular Biology Insights, Inc., Cascade, CO, USA) as follows: forward: 5 0 -AGG AGG GCA GAA TCA TCA CGA-3 0 ; reverse: 5 0 -TGA GGT TTG ATC CGC ATA ATC-3 0 .
Bone marrow immunohistochemistry
Bone marrow biopsy samples were obtained from patients with diagnosis of MM. VEGF immunohistochemical staining of the bone marrow was performed using a labeled streptavidin-biotin peroxidase method, on a Ventana ES automated immunohistochemistry stainer (Ventana Medical Systems, Tucson, AZ, USA) using buffers and detection reagents supplied by the manufacturer. After deparaffinization, the primary antibody (VEGF mouse monoclonal antibody, Santacruz Biotechnology, Santa Cruz, CA, USA, diluted 1:500) was incubated with tissue sections for 24 min. The AEC (amino ethyl carbazole) detection kit (Ventana Medical Systems) was used for antigen visualization; sections were counterstained with a light hematoxylin and then cover slipped with Kaiseri's glycerol jelly (Mayo Medical Laboratories, Rochester, MN, USA). VEGF expression was graded as follows: À, no staining; þ , weak staining (0-30% plasma cells positive); þ þ , weak to moderate staining (30-60% plasma cells positive); þ þ þ , strong staining (460% plasma cells positive).
All patients had given written informed consent for research use of bone marrow and serum specimens. Approval for the study was obtained from the Mayo Institutional Review Board in accordance with federal regulations and the Declaration of Helsinki.
Functional studies
Ability of VEGF to activate intracellular downstream kinases was examined in three different myeloma cell lines. Phosphorylation of the mitogen-activated protein kinase (MAPK) and members of the signal transducers and activators of transcription (Stat) family members Stat1, Stat3 and Stat5 was evaluated after stimulation with differing concentrations of VEGF. Human MM cell lines JJN3, 8226 and OPM2 were maintained in RPMI 1640 containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ ml streptomycin. Cells were starved 16 h in RMPI 1640 and then stimulated with 10, 20 or 50 ng/ml VEGF 121 and VEGF 165 . Cells were washed with phosphate-buffered saline, lysed and centrifuged. Cell lysates (50 mg/lane) were separated by SDS-PAGE prior to transfer to nitrocellulose. The blots were probed with phospho-STAT1, phospho-STAT3 Tyr705, phospho-STAT3 Ser727, phospho-STAT5 and phospho-p44/42 MAPK (Cell Signaling Technology), followed by incubation for 1 h with horseradish peroxidase-conjugated secondary antibodies and visualization with the ECL detection kit (Amersham).
Apoptosis studies
Ability of VEGF to protect from dexamethasone-induced apoptosis was examined using the myeloma cell line MY5. A constant number of cells were exposed to dexamethasone (1.5 mM) or VEGF 121 or VEGF 165 at concentrations of 0, 4, 20 and 50 ng/ml or both. The presence of apoptotic cells was detected by flow cytometry, using 7-AAD as a marker of apoptosis.
Results
VEGF expression by RT-PCR
The presence of VEGF expression by patient plasma cells and the myeloma cell lines was evaluated using RT-PCR. VEGF expression was evident in all the five patient samples studied. Seven different myeloma cell lines (ARH9, OCI-My5, KAS6/1, RPMI 8226, KP6, ANBL-6, U266) were also studied for VEGF expression by RT-PCR. All cell lines demonstrated the presence of VEGF mRNA (Figure 1) . Two different isoforms of VEGF (VEGF and VEGF) were observed in all samples studied. VEGF mRNA expression was quantitated by RT-PCR in eight patient samples and the results were as shown in Figure 2 . Melting curve analysis of the VEGF PCR products was performed demonstrating a clear peak at 831C (Figure 3b ). Further demonstration of the specificity was performed by electrophoresing the PCR products on a 2% agarose gel (Figure 3a) .
VEGF secretion by the plasma cells
VEGF protein secretion by different myeloma cell lines was examined by ELISA on the cell culture supernatants. Rat serum and plasma, human plasma and RPMI medium were used as controls. Six cell lines (ANBL-6, KP6, KAS6/1, OCI-My5, RPMI 8226, OPM2) were studied. The cells were seeded into six-well plates at a concentration of 200 000 cells per well in RPMI 1640 with 10% FBS. Culture supernatants were removed after 96 h and the VEGF measured as previously described. VEGF secretion ranged from 217 to 3050 pg/ml (Figure 4 ) compared to undetectable levels in the normal human plasma.
VEGF expression by immunohistochemistry
The expression of VEGF by myeloma cells was studied by immunohistochemistry in bone marrow biopsy samples from 20 patients with MM. Plasma cells in the bone marrow demonstrated variable expression of VEGF as shown in the representative pictures (Figure 5a-d) . Of the 20 samples, 18 were positive for VEGF expression and the level of expression based on the intensity, and a relatively high level of expression was seen in 13 patients (grade þ þ þ ). Five patients had weak to moderate grade of staining and it was negative in the remaining two. We 
Figure 2
Quantitative RT-PCR for VEGF mRNA. Values are expressed as a ratio of VEGF to GAPDH expression.
Figure 3
Gel demonstrating VEGF amplicon following quantitative PCR carried out on purified myeloma cells from five patient samples (a). Also included are the melting curves from the five patient samples (b).
Vascular endothelial growth factor in myeloma S Kumar et al also noticed some degree of staining by the megakaryocytes in the marrow as well.
Expression of VEGF receptors
We further evaluated the expression of both VEGF receptors, VEGFR1 and VEGFR2, in five sorted myeloma bone marrow samples and in seven different myeloma cell lines (ARH9, OCIMy5, KAS 6/1, 8226, KP-6, ANBL-6, U266) by nested RT-PCR. All the myeloma cell lines expressed VEGFR1 and three of the cell lines (KP6, KAS 6/1, ANBL6) expressed VEGFR2. VEGFR1 expression was present in plasma cells from all five patients, whereas strong expression of VEGFR2 was seen in three patient samples, weak in one and none in the fifth patient (Figures 6 and  7) . The RT-PCR results were confirmed by sequence analysis.
The expression patterns for VEGF and their receptors in the different cell lines are summarized in Table 1 .
Evaluation of VEGF effect on myeloma cells
We were able to demonstrate STAT3 activation by both VEGF 121 and VEGF 165 in the JJN3 myeloma cell line (Figure 8 ). The 
Discussion
In MM, emerging evidence point to the presence of a maze of autocrine and paracrine interactions in the bone marrow between stroma and the malignant plasma cells mediated by various cytokines and growth factors. A variety of cytokines (IL-1b, TNF-a, TGF-b, IL-6, bFGF, VEGF) have been implicated in this complex cascade of interactions. Ongoing studies continue to unravel the interactions between these players in the pathogenesis and progression of MM. VEGF is a heparin binding glycoprotein that is intimately associated with the induction of angiogenesis and endothelial cell proliferation and is an important regulator of vasculogenesis. In addition to its vasculotrophic effects, it also induces vasodilatation, vascular permeability and cellular migration. 24 In addition to the widely studied VEGF-A, this family of cytokines includes VEGF-B, C, D, E and placental growth factor. Although several splice variants of VEGF-A have been found, the two most commonly encountered are VEGF 121 and VEGF 165 . 24 VEGF can be secreted by a variety of cells and its secretion is often stimulated by different cytokines, hypoxia and several activated oncogenes. 25 VEGF activity is mediated mainly through two receptors, VEGFR1 and VEGFR2. 26, 27 Although the affinity of VEGFR1 for its ligand is much stronger than that of VEGFR2, the latter seems to be responsible for most of the angiogenic effect of VEGF. A third receptor (VEGFR3 has been identified and appears to be restricted to lymphatic epithelium.
Figure 7
Detection of flk1/KDR receptors using RT-PCR in sorted myeloma cells from five patients and in different cell lines. Table 1 VEGF and VEGF receptors in myeloma cell lines 
Vascular endothelial growth factor in myeloma S Kumar et al
Bone marrow angiogenesis plays an important role in the pathogenesis and progression of MM as with other hematological malignancies as well as solid tumors. In the setting of myeloma, the degree of bone marrow angiogenesis as estimated by the microvessel density, has been shown to be a powerful prognostic factor for survival. 7, 8 In a study of 400 patients, the degree of bone marrow angiogenesis was found to increase progressively across the spectrum of plasma cell proliferative disorders. 28 Secretion of VEGF by the myeloma cells as shown in our study as well as by others is likely to be playing a role in the initiation and maintenance of the abnormal angiogenesis. The proliferative vascular endothelium is responsive to VEGF stimulation and has been shown to secrete IL-6 on stimulation. 15 IL-6 is a key cytokine regulator of myeloma cell growth 29 and is an essential growth factor for myeloma cells. In the bone marrow, the stromal cells are capable of secreting IL-6 in addition to the vascular endothelial cells. VEGF has been shown to be capable of stimulating IL-6 secretion by the stromal cells 15 and is probably responsible for the increased secretion of IL-6 by stromal cells noted when cocultured with myeloma cells. 30 IL-6 secretion by the bone marrow stromal cells can also be induced by other cytokines like IL-1b and TNF-a. 31 ,32 IL-6 in turn has been shown to be capable of stimulating VEGF secretion by myeloma cells. 15 Thus enough evidence exists to hypothesize the presence of a paracrine feedback loop of cytokines that stimulate, maintain and possibly lead to progression of the myeloma cell mass.
Using multiple methods we have confirmed the increased expression and secretion of VEGF by the myeloma cells using sorted samples from patients with myeloma as well as several established myeloma cell lines. These results confirm work carried out by Bellamy et al, 12 who showed expression of VEGF mRNA and secretion of the corresponding protein by different human hematopoietic tumor cell lines, representing different hematologic malignancies. VEGFR1 receptor expression was found in five of the 12 cell lines studied, suggesting the possibility of an autocrine pathway. Stimulation of vascular endothelial cells by VEGF led to an increase in the mRNA for several hematopoietic growth factors and IL-6. Myeloma cells in the bone marrow were shown to express VEGF, and normal bone marrow myeloid and monocytic cells surrounding the myeloma cells had elevated expression of both the VEGFR1 and VEGFR2 high-affinity VEGF receptors. Dankbar et al 15 studied the paracrine interactions between the myeloma cells and the marrow stromal cells. They demonstrated VEGF expression and secretion by myeloma cell lines and plasma cells isolated from the marrow of patients with MM. However, VEGF receptors VEGFR1 and VEGFR2 expression when evaluated by immunohistochemistry or RT-PCR was found to be weak or absent on the myeloma cells. They found abundant expression of these receptors by marrow stromal cells and also demonstrated recombinant human VEGF-induced, time-and dose-dependent increase in IL-6 secretion by stromal and microvascular endothelial cells. IL-6 is a potent growth factor for myeloma cells, and these findings demonstrate the existence of a paracrine pathway. Podar et al 16 studied the cellular pathways of VEGF stimulation in the myeloma cells and demonstrated stimulation of tumor cell proliferation by VEGF by a protein kinase C-independent Raf-1-MEK-extracellular signal-regulated protein kinase (ERK) pathway.
Most of the previous studies have failed to demonstrate the presence of VEGFR-2 on these cells, 16 although the presence of VEGFR1 has been consistently demonstrated. By using a more sensitive RT-nested-PCR method we have been able to demonstrate its presence on myeloma cells from patient samples as well as on myeloma cell lines. Secretion of VEGF by myeloma cells and the simultaneous presence of both VEGFR1 and VEGFR2 receptors on its surface raise the possibility of an autocrine pattern of stimulation in addition to the paracrine mechanisms discussed previously. The demonstration of VEGFR2 on the myeloma cells is especially important since this seems to be the functionally more active receptor. In this particular context, demonstration of its presence strengthens the biological plausibility for the previously demonstrated effects of VEGF on myeloma cells. 16 We do want to point out that, while demonstration of VEGF required only an RT-PCR approach, a nested approach was needed for demonstrating the VEGF receptors pointing to a low level of expression. However, the level of expression need not correlate with that of activity for cytokine receptors. We were able to demonstrate activation of the MAPK and STAT pathways in some of the cell lines following stimulation with VEGF. But the results of the functional studies fail to demonstrate a significant stimulatory or antiapoptotic effect for VEGF. Further studies are needed to confirm or disprove an autocrine role for secreted VEGF in the disease biology.
The role of VEGF and its receptors in the biology of myeloma as evidenced by our data and other data presents a great opportunity for using inhibitors of VEGF or its receptors for therapy of myeloma. Several novel molecules like SU6668 and PTK787 are currently undergoing evaluation utilizing this strategy. Demonstration of the presence of VEGFR2 in our study provides biological explanation for the preclinical activity observed with VEGFR2 inhibitors. Results of these clinical trials and in vitro studies with these agents will shed more light on the role of this cytokine and its receptors in the biology of myeloma.
